To further evaluate the interaction of M2BPGi with galectin-3 in HCC cells, we subjected the PLC/PRF/5 HCC cell line to immunoprecipitation, and observed stronger M2BP expression (85–97 kDa) in M2BPGi-treated cells than in non-treated cells. The gene discussed is LGALS3; the disease is hepatocellular carcinoma.